MedTrace Logo

Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs

NCT05177991 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-09-26

No results posted yet for this study

Summary

While studies have shown improved postoperative pain control with TAP blocks after inguinal and ventral hernia repair, data comparing Liposomal bupivacaine (Exparel) to bupivacaine alone in formulation of the TAP block is particularly scarce. Therefore, we designed a prospective, randomized trial comparing the postoperative pain control in minimally invasive ventral and inguinal hernia repair patients who receive an Exaparel-based TAP block compared to the traditional bupivacaine (Marcaine) TAP block.

Conditions

  • Inguinal Hernia
  • Ventral Hernia

Interventions

DRUG

Liposomal Bupivacaine

20cc of Liposomal Bupivacaine for TAP block

DRUG

Bupivacaine

20cc of Bupivacaine for TAP block

Sponsors & Collaborators

  • Our Lady of the Lake Hospital

    collaborator OTHER

  • Leslie Son

    lead OTHER

Principal Investigators

  • Leslie Son, PhD · Our Lady of the Lake Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177991 on ClinicalTrials.gov